Semaglutide (also known as Ozempic and Wegovy) does not negatively impact brain health and might even be helpful to lower the risk of memory problems, dementia, and nicotine dependence.
In this study, people (20,000 in each cohort) on semaglutide for Type 2 Diabetes were at a lower risk of cognitive deficit, dementia, and nicotine dependence than matched cohorts of people on other anti-diabetic drugs.
If confirmed in randomised controlled trials, these findings would have important implications for patients, service providers, and public health. They would be particularly welcomed in psychiatry as many people with mental illness also have diabetes and vice versa.